Drs. Melak and Heilman

Tufts Neurosurgeons Honored for Innovation in Hydrocephalus Treatment

By MedTech Intelligence Staff
Drs. Melak and Heilman

Neurosurgeons Adel Malek, M.D., Ph.D., and Carl Heilman, M.D., were recognized for their eShunt System, which is the first minimally invasive treatment for communicating hydrocephalus.

The Society of Vascular and Interventional Neurology (SVIN) has awarded Tufts Medical Center neurosurgeons Adel Malek, M.D., Ph.D., chief of neurovascular surgery, and Carl Heilman, M.D., neurosurgeon-in-chief and chairman of neurosurgery, the 2022 Innovation Award for their work to bring a minimally invasive, endovascular treatment to people with communicating hydrocephalus.

The physicians are co-founders of CereVasc, a clinical-stage, venture-funded, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. They developed the company’s flagship product, the eShunt System, which includes an endovascularly implantable cerebral spinal fluid shunt and delivery components, which are designed to treat CH without invasive surgery.

“Drs. Malek and Heilman have developed a disruptive innovation in the eShunt System that has the potential to meaningfully transform the way that patients with communicating hydrocephalus are treated,” said Ameer Hassan, D.O., FAHA, FSVIN, president of SVIN. “SVIN and the neuroendovascular community will benefit greatly from the work they are doing.”

The award was presented during the SVIN annual meeting in November.

Related Articles

About The Author

MedTech Intelligence